ABOUT GUARDANT360®

The Guardant360 liquid biopsy comprehensive genomic profiling test effectively detects the four main classes of genomic alterations in 74 well-documented cancer genes, thereby enabling clinicians to identify candidates for targeted therapies and to avoid treatments which are less likely to be effective. It is indicated for all advanced solid tumours, both in first line and at progression. Guardant360 includes most guideline recommended genomic biomarkers, in line with those included on the National Genomic Test Directory, and has a very fast turnaround time, with an average of 7 days from sample receipt in the laboratory to issuing of the report.

More than 280 peer-reviewed publications support the clinical value of Guardant360. The test has been used by over 11,000 oncologists worldwide, with more than 250,000 tests performed to date.

LEARN MORE – CONNECT WITH OUR EXPERTS

www.guardanthealth.eu | clientserviceseurope@guardanthealth.com